Prelude to PATHWEIGH: pragmatic weight management in primary care
- PMID: 35997768
- PMCID: PMC10047621
- DOI: 10.1093/fampra/cmac092
Prelude to PATHWEIGH: pragmatic weight management in primary care
Abstract
Objective: Treatment of obesity-related diseases, rather than obesity itself, remains the mainstay of medical care. The current study examined a novel approach that prioritizes weight management in primary care to shift this paradigm.
Methods: PATHWEIGH is a weight management approach consisting of staff team training, workflow system management, and data capture from tools built into the electronic medical record (EPIC). PATHWEIGH was compared to standard of care (SOC) using two family medicine clinics in the same US healthcare system. Descriptive statistics compared patient-, provider-, and clinic-level factors between the groups among those with at least one weight-prioritized visit (WPV) and one follow-up weight over 14 months.
Results: Groups were similar in terms of total patient visits (7,353 vs. 7,984) and patients eligible for a WPV (i.e. >18 years + body mass index >25 kg/m2; 3,746 vs. 3,008, PATHWEIGH vs. SOC, respectively). However, more PATHWEIGH clinic patients (15.9% vs. 8.4%; P < 0.001) received at least one WPV. Although no difference was observed for average patient weight loss over 14 months (P = 0.991), the number of WPVs per patient was higher in PATHWEIGH (P < 0.001) and significantly associated with weight loss (P = 0.001), with an average decrease in weight of 0.55 kg per additional visit.
Conclusions: Results from the current study demonstrate early success in changing the paradigm from treating weight-related comorbidities to treating weight in primary care.
Keywords: obesity; obesity management; patient education; primary health care; public health.
© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Conflict of interest statement
LP has received personal fees for consulting and/or speaking from Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Medscape, WebMD, and UpToDate. JW, AK, EW, and ESK have no conflicts to disclose.
Figures
References
-
- Taksler G. Life-years lost to preventable causes-of-death in the U.S., 2014. Paper presented at: The Society of General Internal Medicine 2017 Annual Meeting; April 19–22, 2017, 2017; Washington, DC.
-
- American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(Suppl 1):S111–S124. - PubMed
-
- World Health Organization. Obesity and overweight. 2018. [accessed 2022 Mar 29]. https://www.who.int/topics/obesity/en/.
-
- Kaplan LM, Golden A, Jinnett K, Kolotkin RL, Kyle TK, Look M, Nadglowski J, O'Neil PM, Parry T, Tomaszewski KJ, et al. .. Perceptions of barriers to effective obesity care: results from the national ACTION study. Obesity. 2018;26(1):61–69. - PubMed
-
- Kushner RF. Barriers to providing nutrition counseling by physicians: a survey of primary care practitioners. Prev Med. 1995;24(6):546–552. - PubMed